



Modus Therapeutics to attend BIO-Europe 2015

STOCKHOLM – 1 November, 2015. Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, will be attending BIO-Europe 2015 in Munich, Germany.

BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry and takes place 2-4 November 2015. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.

For further information, please contact:

Christina Herder, CEO:

Tel: +46 70 374 71 56

E-mail: christina.herder@modustx.com

David Dible/ Pip Batty, Citigate Dewe Rogerson

Tel: +44 20 7638 9571

E-mail: david.dible@citigatedr.co.uk

TO THE EDITORS

About Modus Therapeutics AB

Modus Therapeutics is a Swedish biotech company developing sevuparin - a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe. Sickle Cell Disease patients' red blood cells form a sickled shape, making blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients' blood flow, thereby reducing their pain as well as the amount of time they will need to spend in hospital. Modus Therapeutics plans to develop a presentation of sevuparin that the patient can self-administer allowing them to live a more normal life by terminating early the painful episodes that result in them being hospitalised.

Modus Therapeutics is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB. For more information, please visit www.modustx.com

About Sevuparin

Sevuparin is an innovative, proprietary polysaccharide drug, which has the potential to restore blood flow and prevent further microvascular obstructions, caused by abnormal blood cells in SCD patients. With its anti-adhesive properties, sevuparin could thereby offer treatment of the underlying cause of vaso-occlusive crisis (VOC) in SCD patients, with earlier pain relief, shorter hospital stay, reduced need of opioids and improved quality of life. Modus Therapeutics is currently enrolling patients in a Phase II study with the aim to present data during second half of 2016.